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Background: South Africa (SA) has expanded efforts to reduce mother-to-child transmission of HIV (MTCT) to less
than 2% at six weeks after birth and to less than 5% at 18 months postpartum by 2016. Despite improved
antiretroviral regimens and coverage between 2001 and 2016, there is little data on infant HIV drug resistance. This
paper tracks the prevalence of HIV drug resistance patterns amongst HIV infected infants from three nationally
representative studies that assessed the effectiveness of national programs to prevent MTCT (PMTCT). The first study
was conducted in 2010 (under the dual therapy PMTCT policy), the second from 2011 to 12 (PMTCT Option A
policy) and the third from 2012 to 13 (PMTCT Option A policy). From 2010 to 2013, infant non-nucleoside reverse
transcriptase inhibitor (NNRTI) exposure increased from single dose to daily throughout breastfeeding; maternal
nucleoside reverse transcriptase inhibitor (NRTI) and NNRTI exposure increased with initiation of NNRTI-and NRTI-
containing triple antiretroviral therapy (ART) earlier in gestation and at higher CD4 cell counts.
Methods: Three nationally representative surveys were conducted in 2010, 2011–12 and 2012–13. During the
surveys, mothers with known, unknown, or no exposure to antiretrovirals for PMTCT and their infants were
included, and MTCT was measured. For this paper, infant dried blood spots (iDBS) from HIV PCR positive infants
aged 4–8 weeks, with consent for additional iDBS testing, were analysed for HIV drug resistance at the National
Institute of Communicable Diseases (NICD), SA, using an in-house assay validated by the Centers for Disease Control
and Prevention (CDC). Total viral nucleic acid was extracted from 2 spots and amplified by nested PCR to generate
a ~ 1 kb amplicon that was sequenced using Sanger sequencing technologies. Sequence assembly and editing was
performed using RECall v3.
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Results: Overall, HIV-1 drug resistance was detected in 51% (95% Confidence interval (CI) [45–58%]) of HIV PCR
positive infants, 37% (95% CI [28–47%]) in 2010, 64% (95% CI [53–74%]) in 2011 and 63% (95% CI [47–77%]) in 2012
(p < 0.0001), particularly to the NNRTI drug class. Pooled analyses across all three surveys demonstrated that infants
whose mothers received ART showed the highest prevalence of resistance (74%); 26% (21/82) of HIV PCR positive
infants with no or undocumented antiretroviral drug (ARV) exposure harboured NNRTI resistance.
Conclusions: These data demonstrate increasing NNRTI resistance amongst newly-diagnosed infants in a high HIV
prevalence setting where maternal ART coverage increased across the years, starting earlier in gestation and at
higher CD4 cell counts. This is worrying as lifelong maternal ART coverage for HIV positive pregnant and lactating
women is increasing. Also of concern is that resistant virus was detected in HIV positive infants whose mothers
were not exposed to ARVs, raising questions about circulating resistant virus. Numbers in this group were too small
to assess trends over the three years.
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Preventing mother-to-child transmission (PMTCT) of
HIV has been a global priority for health research and
programmatic implementation over the past two decades.
The global scale-up of antiretroviral (ARV) prophylaxis
for PMTCT has led to two thirds of HIV-infected preg-
nant women in resource limited settings receiving ARVs
for PMTCT, and resulting in a 48% decline in mother to
child HIV transmission between 2009 and 2015 [1]. By
2008, the South African national PMTCT policy recom-
mended maternal combination (triple) antiretroviral treat-
ment (ART), using stavudine (d4T) with lamivudine
(3TC) and efavirenz (EFV) or nevirapine (NVP) if CD4 cell
count was < 200 cells/mm3, or maternal zidovudine (AZT)
prophylaxis from 28weeks gestation with single dose nevi-
rapine (sdNVP) in labour with infant sdNVP and 7 or 28
days of infant AZT. From April 2010, Option A was intro-
duced, wherein lifelong maternal ART, using tenofovir
(TDF) with 3TC or emtricitabine (FTC) and NVP (or
AZT with 3TC and NVP) was initiated if CD4 cell count
was < 350 cells/mm3, or AZT prophylaxis offered from 14
weeks gestation with sdNVP and 3 hourly AZT during
labour and single dose TDF/FTC postpartum; infants re-
ceived daily NVP for six weeks (if not breastfed) or till one
week post breastfeeding cessation. Under Option A, all
HIV-exposed infants received daily nevirapine (NVP) for
six weeks if not breastfeeding or until one week following
cessation of breastfeeding. This study reports data col-
lected during the implementation of Option A in South
Africa. In April 2013, national PMTCT policy transitioned
to WHO PMTCT Option B, and in 2015 to PMTCT Op-
tion B+; the latter recommends initiation and lifelong con-
tinuation of ART amongst all pregnant and lactating
women, regardless of their CD4 cell count. Since 2010,
antiretroviral treatment guidelines recommended that
HIV-infected infants and children less than 3 years of age
should be initiated on a protease-inhibitor (PI) based regi-
men immediately after diagnosis [2, 3].During the time of this study the South African Na-
tional Strategic Plan on HIV, TB and STI’s (2012–2016)
aimed to reduce the risk of MTCT of HIV to less than
2% at six weeks after birth and to less than 5% at 18
months postpartum by 2016 [4]. To this end, the South
African National Department of Health expanded and
improved PMTCT services within the maternal and
child health program. To assess the effectiveness of the
national PMTCT program, three annual, nationally
representative, cross-sectional surveys, each called the
South African PMTCT Evaluation (SAPMTCTE), were
conducted between 2010 and 2013. Each survey aimed
to capture HIV-exposed and HIV-unexposed infants at
4–8 weeks of age, regardless of PMTCT exposure. Dried
blood spots were collected and tested for HIV antibodies
and qualitative polymerase chain reaction (PCR) to de-
termine infant HIV exposure and infection status, re-
spectively. Data demonstrated that rates of early mother
to child transmission of HIV declined from 3.5% (2010)
to 2.7% (2011–12) and to 2.6% (2012–13) at 6 weeks
post-delivery [5–8]. Over the 3 years of surveillance,
infant HIV exposure is estimated to have remained con-
stant; approximately 29–32% of mothers reported being
HIV positive during pregnancy, and 33% of participating
infants were shown to be HIV-exposed at six weeks
post-delivery. In addition, access to HIV testing and care
was high, with more than 90% of mothers receiving
PMTCT interventions.
Resistance to non-nucleoside reverse transcriptase
inhibitors (NNRTI) frequently occurs in HIV-infected
infants following exposure to sdNVP for PMTCT, in-
creasing the risk of virological failure when HIV PCR
positive infants are initiated on NNRTI-containing ART
regimens [9]. Early studies on women and infants receiving
Option A show lower rates of resistance, yet report in-
creased selection of nucleoside reverse transcriptase inhibi-
tor (NRTI) resistance in women receiving AZT from early
(< 20 weeks gestation) in pregnancy [10]. Furthermore, the
Hunt et al. BMC Infectious Diseases 2019, 19(Suppl 1):787 Page 3 of 7use of ultra-sensitive assays that detect resistance-
associated mutations at low frequencies within the circulat-
ing viral subspecies population show even higher propor-
tions of infants harbouring resistance than detected using
routine Sanger (not ultra-sensitive) sequencing assays
[11, 12]. Drug resistance patterns and frequencies in real-
life programmatic settings are less well documented. The
objective of this sub-study was to track the prevalence of
HIV-1 drug resistance (HIVDR) in nationally representa-
tive samples of young infants newly diagnosed with HIV,
enrolled in the three SAPMTCTE surveys, and conducted
in real-life, programmatic settings.Methods
Data for this resistance sub-study were drawn from
the three nationally representative, cross-sectional
SAPMTCTE, conducted amongst infants aged 4–8
weeks receiving their first immunisation. Data were col-
lected at 580 public primary health care clinics and com-
munity health centres in all nine South African provinces
between June – December 2010 (2010 survey), August
2011 – March 2012 (2011 survey), and October 2012 –
May 2013 (2012 survey), respectively [13]. Caregiver/in-
fant pairs of known or unknown HIV and PMTCT status
were consecutively or systematically selected depending
on facility size. Data were gathered from patient-held
charts (“Road to Health Charts/Booklets”) and during
interviews (self-reported maternal HIV testing and HIV
status, infant feeding practices and ARV regimen). Infant
dried blood spots (iDBS) were collected by heel-prick
from all consented infants and assessed for HIV-exposure
using a biomedical marker HIV Enzyme immunoassay
(EIA). The iDBS with positive EIA or discordant EIA re-
sults were compared with self-reported results or were
tested using a qualitative total nucleic acid (TNA) PCR to
determine infant’s HIV infection. All DBS cards were
stored at -20 °C before analysis.
HIVDR genotyping was performed on all adequate
HIV PCR positive iDBS specimens from participants that
had consented for further testing. Specimens from par-
ticipants from whom consent for further testing was not
received, or iDBS cards with insufficient or unusable
blood spots were excluded. Genotyping for resistance
mutations to the NRTI, NNRTI and protease inhibitor
(PI) drug classes was performed using a validated in-
house sequencing method recommended by the CDC
[14] as previously described [15]. Briefly, total viral nu-
cleic acid was extracted from two spots and amplified by
nested PCR to generate a ~ 1 kb amplicon that was
sequenced using Sanger sequencing technologies. Se-
quence assembly and editing was performed using
RECall v3 [16]. Resistance was defined as the presence
of mutations associated with impaired drug susceptibilityusing the Stanford algorithm (https://hivdb.stanford.edu/)
and the 2015 IAS-USA drug resistance mutation list [17].
Group comparisons for categorical data were per-
formed using chi-square tests. Binomial regression
models were applied to estimate absolute differences in
resistance prevalence over the different years and expos-
ure categories. The analyses performed are unweighted
and did not take the survey design into account due to
the small number of HIV positive participants involved.
Summary statistics were calculated using STATA v14
(StataCorp. 2015 Stata Statistical Software: Release 14.
College Station, TX: StataCorp LP).
For the purpose of this analysis we categorised mater-
nal and infant antiretroviral access into five main groups:
maternal ART with infant prophylaxis (NVP or AZT);
maternal ARV prophylaxis with infant prophylaxis (NVP
or AZT); infant prophylaxis only (mother reported not
receiving any antiretroviral drug), any other antiretro-
viral combination including maternal ART only or ma-
ternal ARV only (no infant prophylaxis) or maternal
ART and ARV (not one or the other) for some duration
of pregnancy, and no known maternal antiretroviral
exposure.
The SAPMTCTE was approved by the institutional re-
view board of the SA Medical Research Council (MRC),
study number EC09–002. The project was reviewed
according to the CDC human research procedures and
was determined to be research, but CDC was not en-
gaged. The resistance sub-analysis study was approved
by the Institutional Review Board of the University of
the Witwatersrand (M110737).
Results
Two hundred and eighty-five TNA positive iDBS speci-
mens gathered at 4–8 weeks were identified in the three
SAPMTCTE: 125 in the 2010 survey, 89 in 2011, and 71
in 2012. Of these, 116, 82 and 71 infants were eligible
for inclusion in this sub-study, respectively. Drug resist-
ance testing was therefore performed in a total of 269
iDBS specimens collected from all three surveys, repre-
senting 94% of all positive specimens identified in the
surveys. Two specimens were subsequently removed
from the 2010 survey set because of unresolved phylo-
genetic clustering. Of the 267 iDBS tested, PCR and
genotyping was successful in 220 (82%) specimens: in
101 (101/114; 89%) specimens from the 2010 survey, 78
(78/82, 95%) from the 2011 survey and 41 (41/71, 58%)
specimens from the 2012 survey (Table 1). Forty- seven
specimens did not amplify.
Amongst 220 iDBS sequences analysed, most of the
infants (166/220, 75%) were 6 weeks of age at time of
specimen collection, whilst 17 (8%) were 4–5 weeks of
age, and 37 (17%) were 7–8 weeks of age. One hundred
and fifteen (52%) were female, and 56% were ever
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posed to maternal ART and received daily infant NVP ±
AZT postpartum, whereas 29% were exposed to mater-
nal ARV for PMTCT with daily infant NVP ± AZT
(Table 2). The proportion of HIV PCR positive infants
receiving NVP and exposed to maternal ART increased
from 10% in 2010 to 32% in 2012, whereas the propor-
tion of infants exposed to maternal ARV prophylaxis de-
creased from 33 to 17% in the same period. Within this
subset, 37% of infants were never exposed to any ARVs
or had unknown exposure (Table 2). Unknown exposure
was defined as infants whose caregiver declined to an-
swer or did not recall, or data was not recorded on the
questionnaire.
Drug resistance mutations to the NNRTI class of
drugs were detected in 51% of 220 specimens; 37% (95%
CI [28–46%]) in 2010, 64% (95% CI [53–74%]) in 2011
and 63% (95% CI [48–77%]) in 2012 (p < 0.0001). The
major mutations Y181C and K103N were most preva-
lent, and were present in 27 and 20% of all specimens
respectively. Two thirds of specimens with NNRTI re-
sistance had a single mutation detected. NRTI resistance
was present in 10 (5%) specimens, 4 each in 2010 and
2011, and 2 in 2012. Of these, the M184V/I mutation
was present in 6 sequences. All 10 specimens with de-
tectable NRTI resistance mutations contained NNRTI
resistance i.e. were resistant to both the NRTI and
NNRTI drug classes. PI mutations were uncommon: the
PI mutation M46I was detected in 2 specimens, and ≤ 2
accessory PI mutations were detected in 12 sequences
(L10IV, V11I, K20M and A71V). All specimens clus-
tered with HIV-1 subtype C apart from 1 specimen
which clustered with HIV-1 subtype D.
Non-amplification of 47 specimens was not associated
with infant ART exposure status (p = 0.268) but was as-
sociated with year of specimen collection (p < 0.001, data
not shown). Genotyping PCR amplification in 2012 was
31% lower than previous years, but was consistent across
all exposure categories. Rates of NNRTI resistance de-
tection were not affected by changes in any ARV
exposure categories over the years (p = 0.722, data not
shown).Table 1 Antiretroviral exposure status of 220 HIV-positive infants an
African Prevention of Mother to Child Transmission Evaluations
2010 survey
Maternal ART plus infant NVP +/− AZT 10 (10%)
Maternal ARV plus infant NVP+/− AZT 33 (33%)
Infant NVP+/−AZT only 11 (11%)
Any other ARV combination 10 (10%)
No/unknown exposure 37 (37%)
Total 101
ART triple drug antiretroviral therapy, ARV: antiretroviral therapy administered to prAnalysis of infant resistance in relation to antiretro-
viral drug exposure demonstrated that NNRTI resist-
ance was detected in 74% (95% CI [56–87%]) of
infants exposed to maternal ART plus infant ARV
(daily NVP ± AZT), and in 68% (95% CI [55–79%]) of
infants exposed to maternal ARV prophylaxis plus in-
fant ARV, Table 2. In addition, 64% of infants who
were not exposed to maternal ART/ARV but received
daily infant NVP ± AZT harboured NNRTI resistance.
NNRTI resistance was also present in 26% of infants
with no or unknown exposure to any ARVs. NRTI re-
sistance was more prevalent in infants exposed to ma-
ternal ART (15%, p = 0.034), compared with other
PMTCT regimens, Table 2.
Discussion
We analysed infant HIV drug resistance using specimens
from the 2010, 2011–12 and 2012–13 nationally repre-
sentative South African PMTCT surveys. These mea-
sured 3.5, 2.7 and 2.6% MTCT at 4–8 weeks postpartum
respectively [5, 7, 8]. Mutations associated with HIVDR
were detected in half to two-thirds of the HIV-1 infected
infants participating in these surveys. Prevalence of re-
sistance was lower in 2010 (37%) compared to 64 and
63% in 2011 and 2012, respectively. This corresponded
to a period of transition from a national PMTCT policy
that recommended ART for women with CD4 cell
counts ≤200 cells/mm3 or ARV prophylaxis from 28
weeks with single dose NVP to one that recommended
maternal ART from as soon as possible after diagnosis
for women with higher CD4 cell counts (≤350 cells/
mm3) with six weeks infant NVP or maternal ARV
(AZT) prophylaxis from 14 weeks, and daily infant NVP
throughout breastfeeding (Option A). However, preva-
lence of resistance increased to 64 and 63% in 2011 and
2012 when the national policy had fully transitioned to
PMTCT Option A, with increased infant NNRTI post-
exposure prophylaxis (six weeks or more compared with
sdNVP in the previous policy). Resistance to the NNRTI
drug class only, which was part of all PMTCT policies in
place during these surveys, with increasing infant
NNRTI exposure between 2010 and 2012, was mostalysed for resistance associated mutations over the 3 South
2011–12 survey 2012–13 survey Total
11 (14%) 13 (32%) 34 (15%)
23 (29%) 7 (17%) 63 (29%)
10 (13%) 5 (12%) 26 (12%)
3 (4%) 2 (5%) 15 (7%)
31 (40%) 14 (34%) 82 (37%)
78 41 220
event mother to child transmission
Table 2 Prevalence of resistance associated mutations to non-nucleoside reverse transcriptase inhibitors (NNRTI) and nucleoside
reverse transcriptase inhibitors (NRTI) in 220 HIV-infected infants identified over 3 survey years categorised according to infant
PMTCT exposure
Infant PMTCT exposure: n/N (%) with NNRTI mutations n/N (%) with NRTI mutations
Maternal ART plus infant NVP ± AZT 25/34 (74%) 5/34 (15%)
Maternal ARV plus infant NVP ± AZT 43/63 (68%) 1/63 (2%)
Infant NVP ± AZT only 17/26 (65%) 1/26 (4%)
Other maternal and/or infant ARV 6/15 (40%) 1/15 (7%)
No/unknown maternal and/or infant ARV exposure 21/82 (26%) 2/82 (2%)
Total 112/220 (51%) 10/220 (5%)
ART combination triple drug antiretroviral therapy, ARV antiretroviral therapy administered to prevent mother to child transmission
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was low (~ 5%) of specimens overall. The major NNRTI
mutations Y181C/I and K103N were the most com-
monly detected mutations. Resistance to PIs was negli-
gible. Paediatric antiretroviral treatment policies
recommend abacavir (NNRTI), 3TC (NNRTI) and Kale-
tra (PI) in children < 3 years, or abacavir (NNRTI), 3TC
(NNRTI) and efavirenz (NNRT) in children > 3 years,
therefore we postulate that the increased NNRTI resist-
ance would not impact the efficacy of the PI-containing
treatment regimens used to treat early (< 3 years of age)
paediatric management within the country. Whilst the
NEVEREST study demonstrated that NNRTI resistance
could re-emerge after a wash-out period, following re-
exposure to the selective pressure of the NNRTI, we do
not know what impact this has at programmatic level, in
the current setting where children between 42 weeks
gestation and 3months of age are often treated with
NVP-containing regimens, before switching to PI- (lopi-
navir/ritonavir)-containing regimens. None of the infants
in our setting were on treatment at the time of HIV
diagnosis.
Detection of resistance in infants was more common
amongst those with documented exposure to maternal
and/or infant PMTCT prophylaxis, in that more than
two thirds of infants exposed to PMTCT harboured
resistance. However, among infants with no documented
exposure to PMTCT interventions resistance was de-
tected in 26% of infants.
These findings are similar to those reported from
other studies performed in the southern African region
over the same time frame. NNRTI resistance was de-
tected in 57% PMTCT-exposed HIV-infected infants
aged ≤2 years (median age 19 weeks) in the Johannes-
burg area in 2011 [18]. National surveys to assess resist-
ance levels in infants ≤18 months of age in Swaziland
(2011, median age 4 months) and Zimbabwe (2010,
median age 4months) showed NNRTI HIVDR in 32 and
63% of participants, respectively [19]. In these studies,
NNRTI resistance was more prevalent in infants exposed
to maternal ART and / or extended infant NVP, anddecreased with age. The data contained within this study
are unique in that proportions of resistance in younger
infants predominantly at 6 weeks of age are reported,
drawn from a nationally representative sample of HIV
PCR positive infants, who would have been recently
exposed to PMTCT interventions.
Drug resistance was further detected in a quarter of spec-
imens with no or undocumented exposure to PMTCT in-
terventions, again similar to previous reports, wherein
HIVDR was detected in 9–50% of infants with undocu-
mented PMTCT exposure [18, 19], possibly due to mater-
nal transmission of a resistant virus. These children are at
higher risk of virological failure [3, 20, 21]. As levels of pre-
treatment resistance in children increases [22], early im-
plementation of fully active regimens in HIV-infected chil-
dren remains a priority for treatment programs.
The low rate of specimen amplification in the 2012
specimen set relative to those collected during the other
surveys is concerning, but there does not appear to be
significant changes in infant exposure status over the
years, nor did this lower rate appear to have had an
effect on resistance prevalence estimates. However, the
actual numbers tested for resistance in each exposure
category by year were small, limiting modelling efforts to
determine associations between years and exposure
categories.
The study is limited by reliance on self-reporting of
maternal and infant PMTCT prophylaxis during the
time of data collection for the current pregnancy, and
lack of information on possible PMTCT exposure during
any prior pregnancies. The study further analyses data
from infants predominantly exposed to dual prophylaxis
or option A and therefore does not provide an under-
standing of the impact of prolonged daily NVP exposure
or option B+ on the prevalence of HIV-1 drug resistance
in infants beyond 8 weeks of age. In addition, conven-
tional specimen sequencing strategies were employed to
detect resistance mutations in the iDBS specimens. It
can be expected that more sensitive technologies such as
next generation sequencing will increase the frequency
of drug resistant variant detection in these studies.
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Data from these national surveys illustrate the complex
drug-resistance challenges that arise as more efficacious
antiretroviral therapy is introduced and at earlier time
points. With the policy change to PMTCT Option B+
(life-long ART for all HIV positive pregnant and lactating
women), efforts to administer treatment early, achieve op-
timal adherence and monitor virological suppression regu-
larly during pregnancy and lactation are needed to
facilitate the elimination of MTCT. In the event of vertical
HIV transmission such efforts may prevent maternally-
acquired drug resistance or the development of infant
HIV drug resistance following ARV exposure.
Whilst PMTCT programs have achieved significant
reductions in levels of infant HIV infection, these pro-
grams should strive to provide optimal care, adherence
counselling and virological suppression to pregnant
women to further reduce the risk of HIV transmission
to infants, and especially the transmission of resistant
virus. The high rate of resistance in infants with no or un-
known exposure further confirms that history of PMTCT
is not the only predictor of resistance. Additionally, the
low frequencies of PI resistance, supports the recommen-
dation to treat all infants infected with HIV with PI-based
regimens at the outset; however, the poor palatability of
PI’s, and questionable safety of PIs in children under the
age of 2-weeks to three months and in sick and premature
infants, preclude their unconditional use. In the context of
PMTCT Option B+, more data are needed on the rela-
tionship between maternal ART duration, maternal ART
adherence and the transmission of resistant virus to the
infant, versus transformation of virus into a resistant form
due to infant drug exposure.
Abbreviations
3TC: Lamivudine; ART: Antiretroviral therapy; AZT: Azidothymidine;
d4T: Stavudine; EFV: Efavirenz; FTC: Emtricitabine; HIV: Human
immunodeficiency virus; HIVDR: HIV drug resistance; iDBS: Infant dried blood
spot; MTCT: Mother-to-child transmission of HIV; NICD: National Institute of
Communicable Diseases; NNRTI: Non-nucleoside reverse transcriptase
inhibitor; NRTI: Nucleoside reverse transcriptase inhibitor; NVP: Nevirapine;
PCR: Polymerase chain reaction; PI: Protease inhibitor; PMTCT: Prevention of
mother-to-child transmission of HIV; SAPMTCTE: South African prevention of
mother-to-child transmission of HIV programme evaluation; Sd-NVP: Single




The findings and conclusions in this report are those of the authors and do
not necessarily represent the official position of the funding agencies.
About this supplement
This article has been published as part of BMC Infectious Diseases Volume 19
Supplement 1, 2019: Evaluating the effectiveness of national programmes to
prevent vertical HIV transmission: Methods, results and implications for PMTCT
Option B+ from South Africa. The full contents of the supplement are available
online at https://bmcinfectdis.biomedcentral.com/articles/supplements/
volume-19-supplement-1.Authors’ contributions
GH, TD, DJ, LM and AG conceptualized the manuscript. GH, JL, AS, MK, LM
and AG managed data collection. GH and CL performed data analysis and
LM, TD, DJ, GS, NN and AG advised data analysis and interpretation. GH
drafted the manuscript with significant input from AG, LM, DJ, TD and CL. All
authors read and approved the final manuscript.
Funding
This evaluation was primarily supported by the President’s Emergency Plan for
AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention
(CDC) under the terms of the Cooperative Agreement 1U2GPS001137–02,
1U2GPS001137–03 and 5U2GPS001137–05. The publication of this paper was
supported by the South African Medical Research Council Representatives of
the study sponsor did not participate in the collection of data but did
participate in the study design, analysis and interpretation of data, the writing
of this report and the decision to submit this paper for publication.
Availability of data and materials
The sequences analysed in this manuscripts are available in NCBI Nucleotide
Database GenBank under accession numbers MH568836 - MH569053.
Ethics approval and consent to participate
Ethical approval was obtained through the Ethics Committee at the South
African Medical Research Council and by approval for the research was
granted by the Centers for Disease Control and Prevention, Atlanta. The
resistance testing and analysis was approved by the Human Research Ethics




The authors declare that they have no competing interests.
Author details
1Centre for HIV and STIs, National Institute for Communicable Diseases,
National Health Laboratory Services, Johannesburg, South Africa. 2Faculty of
Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
3US Centers for Disease Control and Prevention, Center for Global Health,
Division of Global HIV/TB, Atlanta, GA, USA. 4School of Public Health,
University of the Western Cape, Bellville, South Africa. 5UNICEF, New York, NY,
USA. 6Health Systems Research Unit, South African Medical Research Council,
Cape Town, South Africa. 7Biostatistics Unit, South African Medical Research
Council, Cape Town, South Africa. 8School of Public Health and Family
Medicine, University of Cape Town, Cape Town, South Africa. 9Department of
Paediatrics, University of Pretoria, Pretoria, South Africa.
Published: 16 September 2019
References
1. UNAIDS: 2014 Progress report on the global plan towards the elimination of
new HIV infections among children by 2015 and keeping their mothers
alive. 2014. Available from https://www.unaids.org/en/resources/
documents/2014/JC2681_2014-Global-Plan-progress. Accessed 2 May 2018.
2. National Department of Health: The South African Antiretroviral Treatment
Guidelines. In. Edited by National Department of Health. Pretoria: National
Department of Health, 2010. Available from http://apps.who.int/
medicinedocs/documents/s19153en/s19153en.pdf. Accessed 2 May 2018.
3. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P,
Chi BH, Cotton MF, Moultrie H, Khadse S, et al. Nevirapine versus ritonavir-
boosted lopinavir for HIV-infected children. N Engl J Med. 2012;366(25):
2380–9.
4. South African National AIDS Council: The National Strategic Plan on HIV, STIs
and TB, 2012-2016. 2011. Available from https://www.hst.org.za/publications/
NonHST%20Publications/hiv-nsp.pdf. Accessed 2 May 2018.
5. Goga A, Dinh T, Jackson D, for the SAPMTCTE study group: evaluation of
the effectiveness of the national prevention of mother-to-child transmission
(PMTCT) programme measured at six weeks postpartum in South Africa,
2010. Published 2012. Available from http://www.mrc.ac.za/sites/default/
files/files/2016-07-12/SAPMTCTE2010.pdf. Accessed 2 May 2018.
Hunt et al. BMC Infectious Diseases 2019, 19(Suppl 1):787 Page 7 of 76. Goga A, Jackson D, Lombard C, Singh M, for the SAPMTCTE study group: Early
(4–8 weeks post-delivery) Population-level Effectiveness of WHO PMTCT Option
A, South Africa, 2012–13. 2015. 2015. Available from http://www.mrc.ac.za/sites/
default/files/files/2016-07-12/SAPMTCTEReport2012.pdf.. Accessed 2 May 2018.
7. Goga A, Dinh T, Jackson D, Lombard C, Delaney K, Puren A, Sherman G,
Woldesenbet S, Ramokolo V, Crowley S, et al. First population-level
effectiveness evaluation of a national programme to prevent HIV
transmission from mother to child, South Africa. J Epidemiol Community
Health. 2015;69:240–8.
8. Goga A, Dinh T, Jackson D, Lombard C, Puren A, Sherman G, Ramokolo V,
Woldesenbet S, Doherty T, Noveve N, et al. Population-level effectiveness of
maternal antiretroviral treatment initiation before or during the first trimester
and infant antiretroviral prophylaxis on early mother-to-child transmission of
HIV, South Africa: implications for eliminating MTCT. J Glob Health. 2016; http://
www.jogh.org/documents/issue201602/jogh-06-020405.pdf.
9. Ton Q, Frenkel L. HIV drug resistance in mothers and infants following use
of antiretrovirals to prevent mother-to-child transmission. Curr HIV Res.
2013;11(2):126–36.
10. Paredes R, Marconi VC, Lockman S, Abrams EJ, Kuhn L. Impact of
antiretroviral drugs in pregnant women and their children in Africa: HIV
resistance and treatment outcomes. J Infect Dis. 2013;207(Suppl 2):S93–100.
11. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy
V, Perre PV, Rouzioux C, Dabis F. Prevalence of resistance to nevirapine in
mothers and children after single-dose exposure to prevent vertical
transmission of HIV-1: a meta-analysis. Int J Epidemiol. 2007;36(5):1009–21.
12. Hunt GM, Coovadia A, Abrams EJ, Sherman G, Meyers T, Morris L, Kuhn L.
HIV-1 drug resistance at antiretroviral treatment initiation in children
previously exposed to single-dose nevirapine. Aids. 2011;25(12):1461–9.
13. Goga A, Dinh TH, Jackson DJ, Lombard C, Puren A, Sherman G, Ramokolo V,
Woldesenbet S, Doherty T, Noveve N, et al. Population-level effectiveness of
maternal antiretroviral treatment initiation before or during the first trimester and
infant antiretroviral prophylaxis on early mother-to-child transmission of HIV,
South Africa: implications for eliminating MTCT. J Glob Health. 2016; in press.
14. Zhou Z, Wagar N, DeVos JR, Rottinghaus E, Diallo K, Nguyen DB, Bassey O,
Ugbena R, Wadonda-Kabondo N, McConnell MS, et al. Optimization of a low cost
and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and
monitoring in resource-limited settings. PLoS One. 2011;6(11):e28184.
15. Salimo AT, Ledwaba J, Coovadia A, Abrams EJ, Technau KG, Kuhn L, Morris
L, Hunt GM. The use of dried blood spot specimens for HIV-1 drug
resistance genotyping in young children initiating antiretroviral therapy. J
Virol Methods. 2015;223:30–2.
16. Woods CK, Brumme CJ, Liu TF, Chui CK, Chu AL, Wynhoven B, Hall TA,
Trevino C, Shafer RW, Harrigan PR. Automating HIV drug resistance
genotyping with RECall, a freely accessible sequence analysis tool. J Clin
Microbiol. 2012;50(6):1936–42.
17. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, Shafer
RW, Richman DD. 2015 update of the drug resistance mutations in HIV-1.
Top Antivir Med. 2015;23(4):132–41.
18. Kuhn L, Hunt G, Technau KG, Coovadia A, Ledwaba J, Pickerill S, Penazzato
M, Bertagnolio S, Mellins CA, Black V, et al. Drug resistance among newly
diagnosed HIV-infected children in the era of more efficacious antiretroviral
prophylaxis. AIDS. 2014;28(11):1673–8.
19. Penazzato M. HIV drug resistance surveillance in children less than 18
months old newly diagnosed with HIV: results from Swaziland and
Zimbabwe. In: World Health Organization, editor. 5th international
workshop on HIV pediatrics. Malaysia: Kuala Lumpur; 2013.
20. Sebunya R, Musiime V, Kitaka SB, Ndeezi G. Incidence and risk factors for
first line anti retroviral treatment failure among Ugandan children attending
an urban HIV clinic. AIDS Res Ther. 2013;10(1):25.
21. Boerma RS, Boender TS, Sigaloff KC, Rinke de Wit TF, van Hensbroek MB,
Ndembi N, Adeyemo T, Temiye EO, Osibogun A, Ondoa P, et al. High levels
of pre-treatment HIV drug resistance and treatment failure in Nigerian
children. J Int AIDS Soc. 2016;19(1):21140.
22. Boerma RS, Sigaloff KC, Akanmu AS, Inzaule S, Boele van Hensbroek M,
Rinke de Wit TF, Calis JC. Alarming increase in pretreatment HIV drug
resistance in children living in sub-Saharan Africa: a systematic review and
meta-analysis. J Antimicrob Chemother. 2017;72(2):365–71.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
